GENERIC DRUGS

​

Stramsen Biotech Inc. also specializes in the manufacturing and distribution of generic medicines, with a focus on developing a comprehensive range of affordable drugs. Our mission is to enhance accessibility to essential medications, particularly in developing countries. We collaborate with third-party manufacturing facilities to distribute generic drugs both domestically and internationally.

 

Stramsen Biotech Inc. aims to secure contracts for the manufacture and distribution of generic drugs to developing countries by partnering with prominent foreign aid donors. These include the European Union (EU), International Monetary Fund (IMF), United Nations Children's Fund (UNICEF), United States Agency for International Development (USAID), Bill & Melinda Gates Foundation, Clinton Foundation, World Bank, and various overseas governments.

 

Our primary objective is to provide patients with sustainable and affordable health solutions. We place particular emphasis on plant-based medicines, which often offer improved safety profiles and fewer side effects compared to synthetic alternatives. In addition to our core focus, we engage in related business activities such as compounding and manufacturing of generic medicines.

 

The U.S. generic drugs market is poised for remarkable growth, with projections indicating an increase from USD 133.59 billion in 2023 to USD 188.44 billion by 2033. This represents a Compound Annual Growth Rate (CAGR) of 3.5% between 2024 and 2033, highlighting the sector's immense potential and stability.

 

The market's expansion is primarily driven by its unparalleled cost-effectiveness, a direct result of the Food and Drug Administration's (FDA) streamlined regulatory pathway. Unlike brand-name drugs, generic medications bypass the substantial expenses associated with replicating original clinical trials for efficacy and safety. This innovative approach not only accelerates market entry but also significantly reduces costs, making essential medications more accessible to millions of Americans.

 

The generic drug segment stands as a beacon of rapid growth and widespread accessibility in the U.S. pharmaceutical landscape. The FDA's unwavering commitment to regulating and promoting generic drugs underscores their critical role in enhancing public health outcomes. This dedication has fostered a competitive environment among manufacturers, dramatically expanding medication availability while driving down costs - a win-win for patients nationwide.

 

The approval of generic alternatives has ushered in a new era of pharmaceutical diversity, bolstering supply stability and mitigating shortage risks. With an astounding 91% of all U.S. prescriptions filled with generic drugs, the market penetration of these cost-effective alternatives is nothing short of revolutionary. The FDA's approval of over 32,000 generic drugs serves as a testament to this segment's profound contribution to healthcare accessibility.

• In a groundbreaking development, February 2024 saw Alvotech and Teva announce the U.S. approval of SIMLANDI (adalimumab-ryvk) injection - the first interchangeable high-concentration, citrate-free biosimilar to Humira. This milestone exemplifies the ongoing innovation and progress in the generic drugs market.

 

Key insights into the U.S. Generic Drugs Market reveal:

• The pure generic drugs segment dominates the market by type, showcasing the preference for these cost-effective alternatives.

• Oral administration remains the preferred route, capturing the largest market share and highlighting patient preference for convenience.

• In therapeutic applications, the cardiovascular segment leads, reflecting the growing demand for affordable heart-related medications.

• Online pharmacies have emerged as the dominant distribution channel, revolutionizing how patients access their medications.

 

From a global perspective, the generic drugs market is set for exponential growth. From USD 465.19 billion in 2023, it's projected to reach USD 779.68 billion by 2033, boasting an impressive CAGR of 5.3% from 2024 to 2033. This global trend underscores the increasing worldwide recognition of generic drugs as a vital component of accessible healthcare.

As we navigate this dynamic landscape, the U.S. generic drugs market stands at the forefront of innovation, accessibility, and cost-effectiveness. Its continued growth promises to reshape the healthcare industry, offering hope and improved quality of life for millions of patients across the nation.